Qiagen N.v. · NYSE:QGEN
Qiagen — Q1 2026 Earnings Presentation
22 slides from Qiagen's earnings presentation, May 6, 2026
Slide 1: Q1 2026 results
Q1 2026 results Committed to solid profitable growth May 6, 2026
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Q1 2026: Overview
Q1 2026: Overview 1 Preliminary Q1 2026: Mixed net sales trends, adj. EPS achieving outlook ● $492 mn net sales (+2% actual, -1% CER vs. ≥1% CER outlook) Net sales Adjusted EPS In $ millions In $ per share ● $0.54 CER adjusted diluted EPS in line with outlook +2% / 2 Strong growth among key pillars,
Slide 4: Sales performance and key developments
Q1 2026: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) -1% • +9% CER growth, +3% CER growth excl. Parse Sample CER(1) technologies • Parse integration progressing well, on track to exceed 483 492 ~$40 mn FY 2026 sales target • -5% CER
Slide 5: Portfolio developments
Q1 2026: Portfolio developments Sample technologies – Parse: Oncology portfolio: QIAstat-Dx: Advancing scalable single-cell sequencing Addressing key oncology research needs Advancing syndromic testing solutions Launch of Evercode® Whole Transcriptome Expansion of genomic profiling solutions Launch
Slide 6: FY 2026 sales outlook: Updated perspectives
FY 2026 sales outlook: Updated perspectives ≥+5% CER ~ -1.5 ppts ~ -2 ppts ~+1-2% CER • Reduced immigration • Cautious U.S. Life testing demand Sciences capital (U.S. / Middle East) spending • OEM customer ordering trends • Middle East conflict 2026 outlook QuantiFERON Life Sciences / Updated 2026 o
Slide 7: FY 2026: Leveraging a solid portfolio to drive growth
FY 2026: Leveraging a solid portfolio to drive growth Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Growth pillars total sales (CER) 2026 CER targets ~$720 mn ~$535 mn ~$100 mn ~$160 mn ~$125 mn ~$1.64 bn (February 2026) Updated Updated 2026 CER ~$1.61 bn ~$720 mn ~$500 mn ~$100 mn ~$160 mn ~$125
Slide 8: 2026 sales outlook: H1 vs. H2 updated perspectives
2026 sales outlook: H1 vs. H2 updated perspectives Updated ~+0.5 ppts ~+4% CER ~+1 ppt ~+2 ppts ~+2 ppts ~ -1-2% CER H1 2026 growth End of NeuMoDx, New Sample tech QuantiFERON Better U.S. Life H2 2026 growth outlook Dialunox headwind systems, new returning to Science environment outlook product laun
Slide 9: Q2 and FY 2026: Updated outlook and assumptions
Q2 and FY 2026: Updated outlook and assumptions (As of April 27, 2026) Q2 2026 outlook FY 2026 outlook Net sales ~ -2% CER ~+1-2% CER Anticipated currency impact(1) Positive impact of ~+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.60 CER ≥$2.43 CER Anticipated currency impact(1) Neut
Slide 10: Appendix
QIAGEN Appendix
Slide 11: Maintaining solid profitability while investing in future growth
Q1 2026: Maintaining solid profitability while investing in future growth Adjusted operating income margin 29.8% ~-1.5 ppts ~-0.7 ppts ~-1.2 ppts ~+1 ppt ~27.4% Q1 2025 Tariffs FX Acquisitions Efficiency program Q1 2026 ppts – Percentage points May 6, 2026 Q1 2026 results 11
Slide 12: Consolidated Statements of Income (unaudited)
Q1 2026: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended March 31, 2026 March 31, 2025 Net sales 492,320 483,456 Cost of sales: Cost of sales 169,459 161,294 Acquisition-related intangible amortization 13,258 13,481 Total cost o
Slide 13: 2026: Quarterly sales by product group
2026: Quarterly sales by product group Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 170 13% 9% Diagnostic solutions(1) 185 -1% -4% Of which QuantiFE
Slide 14: 2026: Quarterly sales by product type and region
2026: Quarterly sales by product type and region Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 445 2% -1% revenues Instruments 48 -2
Slide 15: Reconciliation to adjusted results (unaudited)
Q1 2026: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* First quarter 2026 Reported results 492.3 309.6 84.4 85.8 (17.8) 21 % 68.0 0.33 Adjustments Business integration, acq
Slide 16: Footnotes for reconciliation to adjusted results
Q1 2026: Footnotes for reconciliation to adjusted results (unaudited) a. Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration activities
Slide 17: 2026: Quarterly income statement summary
2026: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 Net sales 492.3 Net sales (CER) 476.7 Gross profit 309.6 Gross profit margin 62.9% Adjusted gross profit 325.4 Adjusted gross profit margin 66.1% Operating
Slide 18: Consolidated Balance Sheets
Consolidated Balance Sheets (In $ thousands, except par value) March 31, December 31, (In $ thousands, except par value) March 31, December 31, 2026 2025 2026 2025 Assets (unaudited) Liabilities and equity (unaudited) Cash and cash equivalents 646,289 839,005 Accrued and other current liabilities 40
Slide 19: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, March 31, Three months ended March 31, March 31, (In $ thousands) 2026 2025 (In $ thousands) 2026 2025 Cash flows from operating activities: Cash flows from financing activities: Net income 68,043 90,758 Capital repayment
Slide 20: Currency impact
Q1 2026: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q1 2026 U.S. dollar 273.0 273.1 57% 0.1 Euro 97.1 87.7 18% -9.4 British pound 18.6 17.2 4% -1.4 Japanese yen 11.7 12.1 3% 0.4 Other currencies 91.8 86.7 18% -5.1 T
Slide 21: Employees as of March 31, 2026
Employees as of March 31, 2026 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q1 2026 Q4 2025 Change Production 291 1,083 139 1,513 1,542 -2% R&D 165 741 50 956 975 -2% Sales 559 812 689 2,060 2,119 -3% Marketing 79 174 67 320 321 0% Administration 78 447 152 677 697 -
Slide 22: Your contacts
Your contacts Daniel Wendorff Vice President Calendar E-mail: Head of Investor Relations ir@qiagen.com QuantiFERON Spotlight Session May 7, 2026 Phone: +49 2103 29 11322 Internet: E-mail: daniel.wendorff@qiagen.com Annual General Meeting June 2026 corporate.QIAGEN.com Q2 2026 results August 2026 Dr.